Bortezomib 1.3 / Daratumumab 16 / Dexamethasone (20/20), Multiple Myeloma, Cycle 1

Indication(s)

• Multiple Myeloma; ICD-10 C90.-, C90.0-

Cycles

Cycle length 21 days, recommended cycles: 1

Protocol sequences

• CASTOR: BORT1.3/DRTM16/DEXA(20/20), MM, C1 (PID817) -|- C2-3 (PID818) -|- C4-8 (PID819) -|- C9+ (PID820)

References

• Palumbo A, Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma., N Engl J Med 2016 Aug 25;375(8):754-66 [PMID]
• Richardson PG, A phase 2 study of bortezomib in relapsed, refractory myeloma., N Engl J Med 2003 Jun 26;348(26):2609-17 [PMID]
• Nooka AK, Managing Infusion Reactions to New Monoclonal Antibodies in Multiple Myeloma: Daratumumab and Elotuzumab., J Oncol Pract 2018 07;14(7):414-422 [PMID]
• Spencer A, Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR., Haematologica 2018 Sep 20; [PMID]
• Palumbo A, How to manage neutropenia in multiple myeloma., Clin Lymphoma Myeloma Leuk 2012 Feb;12(1):5-11 [PMID]

Recommendations

• 07/2017: European Society for Medical Oncology
• 05/2020: National Comprehensive Cancer Network

Links

• Daratumumab: Risiko der Reaktivierung von Hepatitis B [BfARM Risikoinf. Rote Hand etc.]

Important notice

The copyrighted protocols are treatment recommendations. The information contained in this compilation on cytostatic drugs, concomitant medication and other therapeutic procedures, as well as dosage and application information, is continuously reviewed with all due care by the authors and editors involved. Nevertheless, the publishers and authors do not assume any liability for the correctness - also with regard to possible printing errors.

The protocols may not be changed in terms of content.

Diagnosis, indication for therapy and treatment of malignant diseases must be carried out in each individual case by the hematologist and oncologist on his or her own responsibility. The treating physician is obligated to this personal responsibility to weigh in each case before a diagnostic or therapeutic measure, indication, contraindications, dosage and application under consideration of the specialized information or other documents of the manufacturers. This applies in particular to rarely used preparations or preparations that are new to the market.

The publishers and authors assume no liability for the accuracy of the contents. The application is at the own responsibility of the treating physician. ©Onkopti.

Valid since: 15.04.2021